One of the most promising techniques for improving the physicochemical characteristics of APIs—solubility, bioavailability, and stability—is pharmaceutical co-crystallization. This method relies on non-covalent interactions to create a crystalline complex of an API with one or more co-formers, which are tiny organic molecules. Co-crystallization is an alternative to the widely used conventional solid-state modification methods, such as particle size reduction. The method makes it possible to create engineered materials with enhanced drug performance while maintaining the API's therapeutic action. A number of co-crystallization processes, including solvent evaporation, grinding, and slurrying, as well as the fundamental ideas behind their production, are described in the overview that follows. The most common characterization methods used to evaluate co-crystals are X-ray diffraction. The review paper presents spectroscopic and thermal analysis. In keeping with the timeframe of this work, this paper addresses the difficulties and future directions of pharmaceutical co-crystallization, including scalability and regulatory concerns as well as more general issues. The main goal was to advance our knowledge of co-crystallization